We are live on ! Find out more

OPTH

Optimi Health Corp

OPTH

Market cap $28.1M

4.90 USD

-0.08

1.61%

At close Updated Aug 25, 4:00 PM EDT

1 day

-1.61%

5 days

0%

1 month

-0.41%

3 months

-14.19%

6 months

-19.41%

Year to date

-19.41%

1 year

-19.41%

5 years

-19.41%

10 years

-19.41%

About: Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia.

Employees: 9

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Optimi Health Establishes Discretionary Equity Facility

VANCOUVER, British Columbia, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the “Company” or “Optimi”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it has entered into a common shares purchase agreement (the “Purchase Agreement”) with Seven Knots, LLC (“Seven Knots”), establishing an equity line of credit (the “ELOC”) under which the Company has the right, but not the obligation, to sell to Seven Knots up to US$100 million of its common shares from time to time over the term of the facility.

Optimi Health Establishes Discretionary Equity Facility

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Optimi's 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression. The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in September 2025.

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages. The products are available to qualified, authorized clinical research organizations.

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from Health Canada and import authorization from the UK Home Office The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from Health Canada and import authorization from the UK Home Office

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development

Recent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access Ibogaine is under investigation to treat PTSD, opioid use disorder and traumatic brain injury VANCOUVER, British Columbia, June 08, 2026 (GLOBE NEWSWIRE) -- via IBN – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today provided an update on its recently announced Ibogaine Initiative . Optimi has secured naturally derived ibogaine from two sources, in both hydrochloride (HCl) and freebase form.

Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Optimi's 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United States and Europe

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia

Updated TGA recommendations broaden therapist eligibility, accept a wider range of treatment settings, and reinforce Australia's position as the world's leading commercial market for prescribed psilocybin and MDMA VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- via IBN – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage psychedelic pharmaceutical manufacturer, today acknowledged the final recommendations published by the Therapeutic Goods Administration ("TGA") following its targeted consultation on the Authorized Prescriber ("AP") scheme for psilocybin and MDMA. Under the AP scheme, authorized psychiatrists may prescribe Optimi's MDMA for the treatment of post-traumatic stress disorder ("PTSD") and psilocybin for treatment-resistant depression ("TRD") from the Company's GMP-compliant production facility in Canada, making Australia the first country in the world to recognize, and regulate, both substances as medicines for these indications.

Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia

Diamond Equity Research Initiates Coverage on Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN)

New York, May 27, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research LLC, an equity research firm with a focus on small capitalization public companies has initiated coverage of Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN). The research summary below is from a report commissioned by Optimi Health Corp. and produced by Diamond Equity Research.The in-depth 40-page initiation report includes detailed information on Optimi Health's business model, services, industry overview, financials, management profile, and risks.

Diamond Equity Research Initiates Coverage on Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN)

Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date

The 6% naturally derived extract is set to be encapsulated for use in patients suffering from treatment-resistant depression under Australia's Authorised Prescriber Scheme, where no serious adverse events have been reported as of December 2025 Vancouver, British Columbia--(Newsfile Corp. - May 26, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of a production run of naturally derived psilocybin extract measuring approximately 6% psilocybin content, representing the highest-purity botanical psilocybin extract produced by the Company to date. The milestone reflects sustained gains across Optimi's cultivation program.

Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date

See News Rankings

Price charts implemented using Lightweight Charts™